HAVCR2 and lung adenocarcinoma: In patients with lung adenocarcinoma, treatment with anti-Tim-3 antibodies resulted in increased cytotoxicity and IFN-γ production of peripheral NK cells [70], suggesting that Tim-3 could be a target for an immunotherapeutic strategy in EBV-negative PTLD patients.